Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shannon N. Westin & Russell R. Broaddus. (2012) Personalized therapy in endometrial cancer: Challenges and opportunities. Cancer Biology & Therapy 13:1, pages 1-13.
Read now
Read now
Articles from other publishers (26)
Vanktesh Kumar & Navjot Kaur. (2023) A Review on Inhibitory Action of Tyrosine Kinase Inhibitors (TKI) by
Curbing the ATP-Tyrosine Kinase Interactions. Current Signal Transduction Therapy 18:2.
Crossref
Crossref
Flavia D. Toledo, Cecilia L. Basiglio, Ismael R. Barosso, Andrea C. Boaglio, Andrés E. Zucchetti, Enrique J. Sánchez Pozzi & Marcelo G. Roma. (2016) Mitogen-activated protein kinases are involved in hepatocanalicular dysfunction and cholestasis induced by oxidative stress. Archives of Toxicology 91:6, pages 2391-2403.
Crossref
Crossref
James N. Fullerton & Derek W. Gilroy. (2016) Resolution of inflammation: a new therapeutic frontier. Nature Reviews Drug Discovery 15:8, pages 551-567.
Crossref
Crossref
Joyce Liu & Shannon N. Westin. (2016) Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecologic Oncology 141:1, pages 65-71.
Crossref
Crossref
Bilgen Gençler & Müzeyyen Gönül. (2016) Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature. Dermatology Research and Practice 2016, pages 1-6.
Crossref
Crossref
Courtney L. JonesChristy M. GearheartSusan FosmireCristina Delgado-MartinNikki A. EvensenKaren BrideAngela J. WaandersFaye PaisJinhua WangTeena BhatlaDanielle S. BittermanSimone R. de RijkWallace BourgeoisSmita DandekarEugene ParkTamara M. BurlesonPillai Pallavi MadhusoodhanDavid T. TeacheyElizabeth A. RaetzMichelle L. HermistonMarkus MüschenMignon L. LohStephen P. HungerJinghui Zhang, Michael J. Garabedian, Christopher C. PorterWilliam L. Carroll. (2015) MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood 126:19, pages 2202-2212.
Crossref
Crossref
T Macarulla, A Cervantes, J Tabernero, S Roselló, E Van Cutsem, S Tejpar, H Prenen, E Martinelli, T Troiani, B Laffranchi, V Jego, O von Richter & F Ciardiello. (2015) Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. British Journal of Cancer 112:12, pages 1874-1881.
Crossref
Crossref
Xingzhe Ma, Qixue Wang, Ying Liu, Yuanli Chen, Ling Zhang, Meixiu Jiang, Xiaoju Li, Rong Xiang, Robert Q. Miao, Yajun Duan & Jihong Han. (2015) Inhibition of tumor growth by U0126 is associated with induction of interferon-γ production. International Journal of Cancer 136:4, pages 771-783.
Crossref
Crossref
Lindsey N. Micel, John J. Tentler, Aik-Choon Tan, Heather M. Selby, Kelsey L. Brunkow, Kelli M. Robertson, S. Lindsey Davis, Peter J. Klauck, Todd M. Pitts, Esha Gangolli, Robyn Fabrey, Shawn M. O'Connell, Patrick W. Vincent & S. Gail Eckhardt. (2015) Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants. Molecular Cancer Therapeutics 14:2, pages 317-325.
Crossref
Crossref
Felix Zeppernick, Laura Ardighieri, Charlotte G. Hannibal, Russell Vang, Jette Junge, Susanne K. Kjaer, Rugang Zhang, Robert J. Kurman & Ie-Ming Shih. (2014) BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors. American Journal of Surgical Pathology 38:12, pages 1603-1611.
Crossref
Crossref
Silvia Schenone, Marco Radi, Francesca Musumeci, Chiara Brullo & Maurizio Botta. (2014)
Biologically Driven Synthesis of Pyrazolo[3,4-
d
]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies
. Chemical Reviews 114:14, pages 7189-7238.
Crossref
Crossref
Jyoti Asundi, Jennifer A. Lacap, Suzanna Clark, Michelle Nannini, Leslie Roth & Paul Polakis. (2014) MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma. Molecular Cancer Therapeutics 13:6, pages 1599-1610.
Crossref
Crossref
Hejun Lu, Wangyang Tu, Hongbo Fei, Guoji Xu, Qiyue Hu, Lei Zhang, Bing Lin, Jijun Yuan, Junzhao Yin, Aishen Gong, Mimi Wan, Dan Wang, Xiaoyan Zhu, Jun Feng, Qian Wang & Piaoyang Sun. (2014) Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors. Bioorganic & Medicinal Chemistry Letters 24:11, pages 2555-2559.
Crossref
Crossref
Van Anh Trinh, Jennifer E. Davis, Jaime E. Anderson & Kevin B. Kim. (2013) Dabrafenib Therapy for Advanced Melanoma. Annals of Pharmacotherapy 48:4, pages 519-529.
Crossref
Crossref
Sari NatanGalia TsarfatyJudith HorevRoni Haklai, Yoel Kloog & Ilan Tsarfaty. (2013) Interplay between HGF/SF‒Met-Ras signaling, tumor metabolism and blood flow as a potential target for breast cancer therapy. Oncoscience 1:1, pages 30-38.
Crossref
Crossref
Karen E. Sheppard, Carleen Cullinane, Katherine M. Hannan, Meaghan Wall, Joanna Chan, Frances Barber, Jung Foo, Donald Cameron, Amelia Neilsen, Pui Ng, Jason Ellul, Margarete Kleinschmidt, Kathryn M. Kinross, David D. Bowtell, James G. Christensen, Rodney J. Hicks, Ricky W. Johnstone, Grant A. McArthur, Ross D. Hannan, Wayne A. Phillips & Richard B. Pearson. (2013) Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. European Journal of Cancer 49:18, pages 3936-3944.
Crossref
Crossref
Luca Grieco, Laurence Calzone, Isabelle Bernard-Pierrot, François Radvanyi, Brigitte Kahn-Perlès & Denis Thieffry. (2013) Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision. PLoS Computational Biology 9:10, pages e1003286.
Crossref
Crossref
Ruud van der Noll, Suzanne Leijen, Guido H.G. Neuteboom, Jos H. Beijnen & Jan H.M. Schellens. (2013) Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews 39:6, pages 664-672.
Crossref
Crossref
Georgia Hatzivassiliou, Jacob R. Haling, Huifen Chen, Kyung Song, Steve Price, Robert Heald, Joanne F. M. Hewitt, Mark Zak, Ariana Peck, Christine Orr, Mark Merchant, Klaus P. Hoeflich, Jocelyn Chan, Shiuh-Ming Luoh, Daniel J. Anderson, Mary J. C. Ludlam, Christian Wiesmann, Mark Ultsch, Lori S. Friedman, Shiva Malek & Marcia Belvin. (2013) Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501:7466, pages 232-236.
Crossref
Crossref
Ana L. Alessandri, Lirlândia P. Sousa, Christopher D. Lucas, Adriano G. Rossi, Vanessa Pinho & Mauro M. Teixeira. (2013) Resolution of inflammation: Mechanisms and opportunity for drug development. Pharmacology & Therapeutics 139:2, pages 189-212.
Crossref
Crossref
Katarina Zmajkovicova, Veronika Jesenberger, Federica Catalanotti, Christian Baumgartner, Gloria Reyes & Manuela Baccarini. (2013) MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance. Molecular Cell 50:1, pages 43-55.
Crossref
Crossref
Antoine Muchir, Young Kim, Sarah A Reilly, Wei Wu, Jason C Choi & Howard J Worman. (2013) Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skeletal Muscle 3:1, pages 17.
Crossref
Crossref
Andrea C. Boaglio, Andrés E. Zucchetti, Flavia D. Toledo, Ismael R. Barosso, Enrique J. Sánchez Pozzi, Fernando A. Crocenzi & Marcelo G. Roma. (2012) ERK1/2 and p38 MAPKs Are Complementarily Involved in Estradiol 17ß-d-Glucuronide-Induced Cholestasis: Crosstalk with cPKC and PI3K. PLoS ONE 7:11, pages e49255.
Crossref
Crossref
Harvey Wong, Laurent Vernillet, Amy Peterson, Joseph A. Ware, Lillian Lee, Jean-Francois Martini, Peiwen Yu, Congfen Li, Geoffrey Del Rosario, Edna F. Choo, Klaus P. Hoeflich, Yongchang Shi, Blake T. Aftab, Ron Aoyama, Sanh Tan Lam, Marcia Belvin & John Prescott. (2012) Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor. Clinical Cancer Research 18:11, pages 3090-3099.
Crossref
Crossref
Lucy Lee. (2012) Translational biomarker in oncology early clinical development: decision case study for MEK inhibitors in healthy volunteer studies. Clinical Investigation 2:2, pages 215-223.
Crossref
Crossref
Lyn M. Wancket, W. Joshua Frazier & Yusen Liu. (2012) Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sciences 90:7-8, pages 237-248.
Crossref
Crossref